Advertisement
CRIS vs ORMP
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRIS is a StrongBuy and ORMP is a Hold.
CRIS's RSI Oscillator remains in oversold zone for 21 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
CRIS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRIS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CRIS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.200) is normal, around the industry mean (3.035). P/E Ratio (0.106) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (3.280) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. CRIS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ORMP's Indicator enters downward trend
The Aroon Indicator for ORMP entered a downward trend on October 23, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator formed such a pattern. In 153 of the 186 cases the stock moved lower. This puts the odds of a downward move at 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 70 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
ORMP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ORMP crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Indicator exited the oversold zone, 22 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORMP advanced for three days, in 216 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.541) is normal, around the industry mean (3.043). P/E Ratio (0.974) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.242) settles around the average of (133.535) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CRIS | ORMP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 68 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 15 | |
PRICE GROWTH RATING 1..100 | 98 | 44 | |
P/E GROWTH RATING 1..100 | 96 | 93 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ORMP's Valuation (68) in the Pharmaceuticals Other industry is in the same range as CRIS (79) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CRIS’s over the last 12 months.
ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CRIS (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CRIS’s over the last 12 months.
ORMP's SMR Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for CRIS (100) in the Biotechnology industry. This means that ORMP’s stock grew significantly faster than CRIS’s over the last 12 months.
ORMP's Price Growth Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for CRIS (98) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than CRIS’s over the last 12 months.
ORMP's P/E Growth Rating (93) in the Pharmaceuticals Other industry is in the same range as CRIS (96) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CRIS’s over the last 12 months.
| CRIS | ORMP | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 73% |
| Stochastic ODDS (%) | N/A | 2 days ago 71% |
| Momentum ODDS (%) | N/A | 2 days ago 78% |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| Advances ODDS (%) | N/A | 20 days ago 82% |
| Declines ODDS (%) | 6 days ago 90% | 3 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRIS’s FA Score shows that 0 FA rating(s) are green while ORMP’s FA Score has 1 green FA rating(s).
- CRIS’s FA Score: 0 green, 5 red.
- ORMP’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRIS’s TA Score shows that 2 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).
- CRIS’s TA Score: 2 bullish, 2 bearish.
- ORMP’s TA Score: 4 bullish, 5 bearish.
Price Growth
CRIS (@Biotechnology) experienced а -5.11% price change this week, while ORMP (@Biotechnology) price change was +1.47% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
CRIS is expected to report earnings on Nov 05, 2026.
ORMP is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ORMP and
Correlation & Price change
A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with DRTS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then DRTS could also see price increases.
| Ticker / NAME | Correlation To ORMP | 1D Price Change % | ||
|---|---|---|---|---|
| ORMP | 100% | +0.24% | ||
| DRTS - ORMP | 53% Loosely correlated | +2.02% | ||
| INO - ORMP | 44% Loosely correlated | +6.94% | ||
| MBIO - ORMP | 44% Loosely correlated | +0.22% | ||
| CGEM - ORMP | 42% Loosely correlated | -3.69% | ||
| CGEN - ORMP | 41% Loosely correlated | -1.02% | ||
More | ||||